<DOC>
	<DOCNO>NCT00635089</DOCNO>
	<brief_summary>This study open-label study subject receive active drug , reslizumab . Subjects able enter trial completion study Res-05-0002 ( NCT00538434 ) . The goal study show long term safety efficacy pediatric subject eosinophilic esophagitis .</brief_summary>
	<brief_title>Open-Label Extension Study Reslizumab Pediatric Subjects With Eosinophilic Esophagitis</brief_title>
	<detailed_description>Subjects enter open-label extension study complete placebo-controlled , double-blind study Res-5-0002 ( NCT00538434 ) . The end study visit Res-05-0002 serve screen visit trial . All subject receive reslizumab follow principal investigator unblinded fashion . Visits administration reslizumab monthly .</detailed_description>
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<criteria>Informed consent Received least two dos study drug Study Res050002 ( NCT00538434 ) Did withdraw Study Res050002 due drug relate adverse event Completed End Treatment Visit Study Res050002 Pregnant nursing female Concurrent Immunodeficiency Current use immunosuppressive drug Did tolerate study drug Study Res050002</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Eosinophilic Esophagitis</keyword>
	<keyword>Cinquil</keyword>
</DOC>